Scandinavian Ear Reconstruction Centre, Dept of Plastic and Reconstructive Surgery, SWEDEN

Similar documents
Hospital Universitario de Getafe (Getafe Universitary Hospital), Spain

The Centre for Disease Prevention and Control, Latvia

Central Manchester University Hospitals NHS Foundation Trust, UK

Hospital Carlos Haya. Malaga, Spain

Department of Medical Genetics, Medical School, University of Athens, Greece

National Center for Tumor Diseases (NCT) Heidelberg, Germany

Ministry for Health, the Elderly and Community Care, Malta

INSTITUTE OF CHILD HEALTH, Greece

European Society of Cardiology, France

SERVICIO DE NEUROCIRUGÍA PEDIÁTRICA. HOSPITAL UNIVERSITARIO 12 DE OCTUBRE, Spain

RED CELL PATHOLOGY UNIT. HOSPITAL CLINIC-UNIVERSITY OF BARCELONA, Spain

Radboud University Nijmegen Medical Centre, department of Neurology, Netherlands

Castilla y leon Regional Health Service (Gerencia Regional de Salud de Castilla y León)

Schoen Kliniken group, Schoen Klinik Hamburg Eilbek, Dept. of neurology and. neurorehabilitation, Germany

Erasmus MC, Center for lysosomal and metabolic diseases, Netherlands

Cystic Fibrosis Europe (CFE), Germany

Riga East University hospital stationary Infectology Center of Latvia (RAKUS LIC), Latvia

VSOP, Lupus Netherlands

UNION EUROPÉENNE DES MÉDECINS SPÉCIALISTES

European Haemophilia Consortium

ERN board of Member States

EUCERD RECOMMENDATIONS QUALITY CRITERIA FOR CENTRES OF EXPERTISE FOR RARE DISEASES IN MEMBER STATES

European Reference Networks (ERN) Guide for patient advocates

Job Description. Clinical Nurse Specialist in Breast care. An overview of Breast Cancer Services at the UPMC Beacon Hospital.

EUCERD RECOMMENDATIONS on RARE DISEASE EUROPEAN REFERENCE NETWORKS (RD ERNS)

WORK PLAN 2017 LAURENCE BALLIEUX NATIONAL FOCAL POINT. 1 EU 3rd HEALTH PROGRAMME

ERN Assessment Manual for Applicants 2. Technical Toolbox for Applicants

BELGIAN EU PRESIDENCY CONFERENCE ON RHEUMATIC AND MUSCULOSKELETAL DISEASES (RMD)

1. Have you or a member of your family had first-hand experience of an adverse event or experienced harm in a healthcare setting in your country?

REPORT FROM THE COMMISSION TO THE EUROPEAN PARLIAMENT AND THE COUNCIL. Report on the interim evaluation of the «Daphne III Programme »

ERN Assessment Manual for Applicants

1. Have you or a member of your family had first-hand experience of an adverse event or experienced harm in a healthcare setting in your country?

Council, 25 September 2014

Member webinar: What is an ideal European Reference Network? Matt Johnson, EURORDIS 10 February 2016

European Reference Networks: strategic value for the Member States. Perspective of France

ERC Grant Schemes. Horizon 2020 European Union funding for Research & Innovation

European Reference Networks. Guidance on the recognition of Healthcare Providers and UK Oversight of Applications

Legal and financial issues Evaluation process

National Plans for Rare Diseases The French plan Ségolène Aymé Orphanet On behalf of Alexandra Fourcade French Ministry of Health

116 Help Lines for Rare Diseases

Spreading Excellence and Widening Participation in Horizon 2020

Presenting the European Investment Advisory Hub Annual Forum of the EUSDR, 2015 Ulm. European Investment Advisory Hub 1

Background paper. Cross-border healthcare in the EU

MARIE SKŁODOWSKA-CURIE ACTIONS. Individual Fellowships (IF) Date: in 12 pts. David WIZEL Research Executive Agency. 18 March 2016 Split

Education and Training Committee, 5 June 2014

Summary of a Survey on the Europe 2020 Flagship Initiative Innovation Union. Executive Summary

Quality. Compassion. Care. Capio IPO. December, Olof Bengtsson, Capio AB (Publ)

European Investment Advisory Hub

1. Have you or a member of your family had first-hand experience of an adverse event or experienced harm in a healthcare setting in your country?

The Pharmaceutical Risk Assessment Committee (PRAC) of the EMA

The Seventh Framework Programme for candidate and potential candidate countries European Regional Economic Forum Nova Gorica, 30 May 2007

EFPIA Code of Practice on relationships between the pharmaceutical industry and patient organisations

Newsletter 2, Spring 2010

Simona Bovha, CPCM European Investment Bank. European Investment Advisory Hub

ANNEX I TO VIII ANNEX I. Health Programme Work Programme for 2017

Do terms like FP6, CORDIS, Specific Programme, Call for

2nd European Reference Networks Conference 8-9 October Lisbon, Portugal. A report by: G Porto & F Courtois

European Social Fund

EUCERD Joint Action WP7 Workshop From Centres of Expertise for Rare Diseases to European Reference Networks

Supportive Care Roundtable

Delegations will find below the above-mentioned Council conclusions, as endorsed by the Council (General Affairs) on 14 September 2015.

Delivering surgical services: options for maximising resources

Synergies between funding sources to large infrastructure. Louis-Philippe Carrier, Smart Development expert, JASPERS Prague, 3 March 2016

Document: Report on the work of the High Level Group in 2006

Healthcare in Europe and in the USA

Call for Nominations. CARLOS V European Award

1. The Working Party on Public Health discussed and agreed the draft Council conclusions as set out in the Annex.

Implementing the 3rd Health Programme. Ingrid Keller Coordinator Health Programme Consumer, Health and Food Executive Agency

The ERC funding strategy

A European workforce for call centre services. Construction industry recruits abroad

Copernicus Incubation Programme

EUROPEAN JOINT TASK FORCE IV. WONCA perspective

Assessment of Erasmus+ Sports

A short paper for ENVI & IMCO MEPs Two solutions to improve recognition of specialisms in the Chapter III professions

ehealth in caring for people with multimorbidity in European countries

Erasmus Mundus José Gutiérrez Fernández Erasmus Mundus Programme Coordinator EACEA

Introduction to ibmg. Marco Varkevisser Director of Education

European network of paediatric research (EnprEMA)

Revised 11/08/2014. Call for proposals VERKET FÖR INNOVATIONSSYSTEM - SWEDISH GOVERNMENTAL AGENCY FOR INNOVATION SYSTEMS

Jean Monnet support to associations

European Investment Advisory Hub

Advanced Medical Training Fellowship in Plastic and Reconstructive Surgery. Ref: TG Closing date: 17 th February 2018

European Quality Assurance Scheme for Breast Cancer Services

EPF Workshops on Cross-Border Healthcare 1st Stop: Croatia Meeting Report

Evolution of Nursing in Europe

APPENDIX ONE. ICAT: Integrated Clinical Assessment Tool

European network of paediatric research (EnprEMA)

WE ARE LOOKING FOR A PROJECT MANAGER

About the European Science Foundation

Spreading knowledge about Erasmus Mundus Programme and Erasmus Mundus National Structures activities among NARIC centers. Summary

NATIONAL HEALTH SERVICE, ENGLAND

Continuing Professional Development From an international perspective

JOINT DECLARATION ON THE PROMOTION AND THE ENFORCEMENT OF CANCER PATIENTS RIGHTS

From FP7 to Horizon 2020 New approaches to speed up innovation and market in the water

The Norwegian innovation and development scheme for news and current affairs media

Briefing Paper: Cross-border EU healthcare directive. England and Wales

European Solidarity Corps

Call for the expression of interest Selection of six model demonstrator regions to receive advisory support from the European Cluster Observatory

Terms of reference. for the Council of European Specialist Medical Assessment

OpenPEPPOL Guidance on the Connecting Europe Facility (CEF)

Transcription:

Scandinavian Ear Reconstruction Centre, Dept of Plastic and Reconstructive Surgery, SWEDEN 1.1 Please indicate the type of organisation on behalf of which you are responding to this consultation: Please indicate what type: 1. Respondent Profile Healthcare provider In hospital specialised service or unit Please indicate for what the administration is responsible: 1.1.1. Other (please specify): Plastic Surgery Department 1.2 Please indicate the name of your organisation or centre: Scandinavian Ear Reconstruction Centre, Dept of Plastic and Reconstructive Surgery, 1.3 Please indicate the country where your organsation/centre is located/has its headquarters or main representative office in Europe: SE 1. Please indicate the number of EU Member States and EEA countries (rway, Iceland, Lichtenstein) and accessing country (Croatia) in which your organisation conducts business/is represented: 1.5 If need be, can we contact you by e-mail to obtain further information on your submission? 1.5.1 Please provide an e-mail address where we can contact you: sven-olof.wikstrom@med.lu.se 1.6 Please provide us with a contact person (incl jobtitle and daytime phone number): 1.7 Please provide additional contact details if needed: dr Sven Olof Wikstrom +6 33 6589

2. Involvement of your organisation in the matter of centres of excellence/reference (COE) and healthcare networks in highly specialised healthcare (HSHC). 2.1 How would you describe your organisation's knowledge of CoE and HSHC? 2.1.1 Space for further comments: 2.2. What aspects or domains related to the topic of CoE and HSHC would correspond to your organisation's key knowledge? (cross any that applies) 2.2.1. Space for further comments: Ear reconstruction 2.3 Is highly specialised healthcare a priority in your organisation's strategies and work plans? 2.3.1 Space for further comments: 2.. What specific field of healthcare services/specialities are most relevant for your centre/organisation's field of work? Poor Professional performance, clinical practice, quality and safety of specialized healthcare High Surgical speciality Please specify: 2.5. Has your organisation/centre been directly involved in the design Occasionally or assessment of professional standards and criteria related with highly specialised healthcare? Reconstructive Plastic Surgery 2.5.1 Please describe your role in such actions/projects: Have participated in forming national guidelines for ear reconstruction 2.6. Has your organisation been involved in projects/activities supported by the Commission in relation with HSHC or professional and technical criteria/standards in highly specialised healthcare?

2.7. Do you have concrete examples based on your own organisation's experience or could you provide us with references or links to documents related with professional criteria and standards in highly specialised healthcare/coe or HSHC (e.g. quality criteria, guidelines, consensus documents)? 2.7.1 Space for further comments: 2.8. Is your centre or unit directly involved in the management (diagnosis, treatment etc.) of highly specialised diseases or conditions? 2.9. Is your centre or unit designated or recognised as centre of reference/excellence in your country? 2.10. How has your centre been designated/recognised as centre of reference/excellence? Based on professional recognition 2.10.1 Space for further comments: Already in 2000 we were listed as highly specialized national center for ear reconstruction by the swedish medical board 2.11. Which is your area of expertice as centre of reference? (please provide your answer in free text) 2.12 Is your centre participating currently in a network of centres of expertise? 2.13. What is the scope of the network? International Ear reconstruction with autologeous rib cartilage 2.1. Which kind of network? International 2.1.1 Space for further comments: Being president of the newly formed International Society for Auricular Reconstruction ISAR www.isar.cc

2.15. Would you be interested in applying to the process to be considered Centre of Excellence of the future European Reference Network? (1 = not interested at all, 5 = very interested) 5 2.15.1 Space for further comments: 3. Proposed criteria for ERN (scope, general and specific criteria) 3.1 Criteria related with diseases or conditions in order to be considered under the scope of the ERN 3.1.1. Need of highly specialised healthcare 5 3.1.1.1. Complexity of the diagnosis and treatment 5 3.1.1.2. High cost of treatment and resources 3 3.1.1.3. Need of advanced/highly specialised medical equipment or infrastructures 3.1.2. Need of particular concentration of expertise and resources 5 3 3.1.2.1. Rare expertise/need of concentration of cases 5 3.1.2.2. Low prevalence/incidence/number of cases 3.1.2.3. Evaluated experiences of Member States 3 3.1.3. Based on high-quality, accessible and cost-effective healthcare 3 3.1.3.1. Evidence of the safety and favourable risk-benefit analysis 3

3.1.3.2. Feasibility and evidence of the value and potential positive outcome (clinical) 3.1.. Do you recommend any additional criteria or option that would effectively address the issue? 3.1.5. Would you prioritise or suggest any concrete disesase or group of diseases to be addressed by the future ERN according to the above criteria? 3.1.5.1 Explain your proposal in free text: Microtia 3.2. General criteria of the centres wishing to join a European Reference Network 3.2.1. Organisation and management 3.2.2. Patients empowerment and centered care 3.2.3. Patient care, clinical tools and health technology assessment 3.2.. Quality, patient safety and evaluation framework policies 3.2.5. Business continuity, contingency planning and response capacity 3 3.2.6. Information systems, technology and e-health tools and applications 3.2.7. Overall framework and capacity for research and training 3 3.2.8. Specific commitment of the management/direction of the centre/hospital to ensure a full and active participation in the ERN 5 3.2.9. Do you recommend any additional option that would effectively address the issue?

3.2.9.1. Space for further comments: 3.3.1. Competence, experience and good outcomes and care 5 3.3. Specific criteria regarding the areas of expertise 3.3.2. Specific resources and organisation: 3 3.3.2.1. Human resources 3 3.3.2.2. Team/centre organisation 3.3.2.3. Structural conditions 3.3.2.. Specific equipment 3.3.2.5. Presence and coordination with other required complementary units or services 3.3.3. Patient care pathways, protocols and clinical guidelines in the field of expertise 3.3.. External coordination, care management and follow-up of patients 3.3.5. Research, training, health technology assessment in the field of expertise 3.3.6. Specific information systems 3 3 3.3.7. Do you recommend any additional criteria or option that would effectively address the issue? 3.3.7.1. Space for further comments: For us it is very important that the surgical treatment of microtia (ear deformities) is concentrated to limited number of centres of excellence in Europe.